Cargando…

Transparent cap-assisted endoscopic injection sclerotherapy for the treatment of patients with esophageal varices

The aim of this study was to compare the efficacy and safety of cap-assisted endoscopic injection sclerotherapy (EIS) versus direct EIS in the management of esophageal variceal bleeding in patients with cirrhosis. This retrospective study included patients with cirrhosis and esophageal variceal blee...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jing, Zhang, Xiaohua, Zhao, Shulei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7302636/
https://www.ncbi.nlm.nih.gov/pubmed/32541523
http://dx.doi.org/10.1097/MD.0000000000020721
_version_ 1783547889887215616
author Wang, Jing
Zhang, Xiaohua
Zhao, Shulei
author_facet Wang, Jing
Zhang, Xiaohua
Zhao, Shulei
author_sort Wang, Jing
collection PubMed
description The aim of this study was to compare the efficacy and safety of cap-assisted endoscopic injection sclerotherapy (EIS) versus direct EIS in the management of esophageal variceal bleeding in patients with cirrhosis. This retrospective study included patients with cirrhosis and esophageal variceal bleeding who underwent EIS with or without the use of a transparent cap at Shandong Provincial Hospital between December 2014 and April 2017. Patients were divided into two groups: Group A (EIS with transparent cap, n = 50) and Group B (direct EIS, n = 45). Data collected included patients’ demographics, procedure details, and rates of variceal eradication, variceal rebleeding, variceal recurrence, and survival during the follow-up period. All data were expressed as mean ± SD. Quantitative variables were compared with Student t test; qualitative variables were compared with the Fisher exact test or chi-square test. P values less than .05 were considered significant. The mean follow-up duration was similar in both groups (16.3 ± 10.2 mo in Group A and 15.5 ± 9.5 mo in Group B). The volume of sclerosant (64.86 ± 10.62 vs 104.73 ± 21.25 ml, P = .044), mean number of sessions (2.37 ± 1.15 vs 5.70 ± 1.57, P = .042), time required to perform endoscopic treatment (6.57 ± 1.50 vs 11.22 ± 2.29 minutes, P = .049), and time to initial esophageal varices eradication (5.43 ± 1.38 vs 8.93 ± 1.5 wk, P = .041) were significantly smaller in the cap-assisted EIS group than in the direct EIS group. The probability of variceal recurrence and rebleeding was significantly higher in the direct EIS group than in the cap-assisted EIS group (14% versus 35.6% and 20% versus 40%). Only 22 patients (44%) developed complications in the cap-assisted group versus 30 patients (66.7%) in the EIS group (P = .039). The probability of survival was similar in both groups (86% versus 75.6%, P = .133). Modified EIS with the use of a transparent cap resulted in lower rates of esophageal variceal recurrence, rebleeding, and complications, compared with direct EIS.
format Online
Article
Text
id pubmed-7302636
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-73026362020-06-29 Transparent cap-assisted endoscopic injection sclerotherapy for the treatment of patients with esophageal varices Wang, Jing Zhang, Xiaohua Zhao, Shulei Medicine (Baltimore) 4500 The aim of this study was to compare the efficacy and safety of cap-assisted endoscopic injection sclerotherapy (EIS) versus direct EIS in the management of esophageal variceal bleeding in patients with cirrhosis. This retrospective study included patients with cirrhosis and esophageal variceal bleeding who underwent EIS with or without the use of a transparent cap at Shandong Provincial Hospital between December 2014 and April 2017. Patients were divided into two groups: Group A (EIS with transparent cap, n = 50) and Group B (direct EIS, n = 45). Data collected included patients’ demographics, procedure details, and rates of variceal eradication, variceal rebleeding, variceal recurrence, and survival during the follow-up period. All data were expressed as mean ± SD. Quantitative variables were compared with Student t test; qualitative variables were compared with the Fisher exact test or chi-square test. P values less than .05 were considered significant. The mean follow-up duration was similar in both groups (16.3 ± 10.2 mo in Group A and 15.5 ± 9.5 mo in Group B). The volume of sclerosant (64.86 ± 10.62 vs 104.73 ± 21.25 ml, P = .044), mean number of sessions (2.37 ± 1.15 vs 5.70 ± 1.57, P = .042), time required to perform endoscopic treatment (6.57 ± 1.50 vs 11.22 ± 2.29 minutes, P = .049), and time to initial esophageal varices eradication (5.43 ± 1.38 vs 8.93 ± 1.5 wk, P = .041) were significantly smaller in the cap-assisted EIS group than in the direct EIS group. The probability of variceal recurrence and rebleeding was significantly higher in the direct EIS group than in the cap-assisted EIS group (14% versus 35.6% and 20% versus 40%). Only 22 patients (44%) developed complications in the cap-assisted group versus 30 patients (66.7%) in the EIS group (P = .039). The probability of survival was similar in both groups (86% versus 75.6%, P = .133). Modified EIS with the use of a transparent cap resulted in lower rates of esophageal variceal recurrence, rebleeding, and complications, compared with direct EIS. Wolters Kluwer Health 2020-06-12 /pmc/articles/PMC7302636/ /pubmed/32541523 http://dx.doi.org/10.1097/MD.0000000000020721 Text en Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0
spellingShingle 4500
Wang, Jing
Zhang, Xiaohua
Zhao, Shulei
Transparent cap-assisted endoscopic injection sclerotherapy for the treatment of patients with esophageal varices
title Transparent cap-assisted endoscopic injection sclerotherapy for the treatment of patients with esophageal varices
title_full Transparent cap-assisted endoscopic injection sclerotherapy for the treatment of patients with esophageal varices
title_fullStr Transparent cap-assisted endoscopic injection sclerotherapy for the treatment of patients with esophageal varices
title_full_unstemmed Transparent cap-assisted endoscopic injection sclerotherapy for the treatment of patients with esophageal varices
title_short Transparent cap-assisted endoscopic injection sclerotherapy for the treatment of patients with esophageal varices
title_sort transparent cap-assisted endoscopic injection sclerotherapy for the treatment of patients with esophageal varices
topic 4500
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7302636/
https://www.ncbi.nlm.nih.gov/pubmed/32541523
http://dx.doi.org/10.1097/MD.0000000000020721
work_keys_str_mv AT wangjing transparentcapassistedendoscopicinjectionsclerotherapyforthetreatmentofpatientswithesophagealvarices
AT zhangxiaohua transparentcapassistedendoscopicinjectionsclerotherapyforthetreatmentofpatientswithesophagealvarices
AT zhaoshulei transparentcapassistedendoscopicinjectionsclerotherapyforthetreatmentofpatientswithesophagealvarices